Maria Törnsén, a seasoned pharmaceutical executive, has joined the board of directors of Germany-based Immunic Inc as it advances its lead asset for multiple sclerosis in the clinic. Simultaneously, Jan Van den Bossche has stepped down from the board. Ms Törnsén joins from Passage Bio Inc, a genetic medicines company, where she was chief commercial officer since July 2021. Prior to this, she was general manager at Sarepta Therapeutics Inc. She has also managed rare disease products at Sanofi SA and before that, held commercialisation positions in endocrine and rare diseases at Shire Plc. Ms Törnsén holds a Master of Science in international business administration from Lund University in Sweden.
Immunic announced the appointment on 6 July 2022.
Copyright 2022 Evernow Publishing Ltd